We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





Snibe Diagnostic SARS-CoV-2 Antigen Assay Secures CE Mark

By LabMedica International staff writers
Posted on 17 Mar 2021
Print article
Image: Maglumi SARS-CoV-2 Ag (CLIA) Kit (Photo courtesy of Snibe Diagnostic)
Image: Maglumi SARS-CoV-2 Ag (CLIA) Kit (Photo courtesy of Snibe Diagnostic)
Snibe Diagnostic (Shenzhen, China) has received CE-IVD marking for its Maglumi SARS-CoV-2 Ag antigen test and has launched the test in countries accepting the designation.

The MAGLUMI SARS-CoV-2 Ag with CE mark is a chemiluminescence immunoassay solution for the quantitative detection of nucleocapsid antigens of SARS-CoV-2 in nasopharyngeal and oropharyngeal swab samples taken from suspected COVID-19 patients. The assay has demonstrated 97.7% sensitivity and 99.6% specificity, and could aid in the early detection of SARS-CoV-2 virus from suspected COVID-19 cases.

The MAGLUMI SARS-CoV-2 Ag assay runs on all MAGLUMI fully-auto chemiluminescence immunoassay analyzers which are widely available around the world. The SARS-CoV-2 antigen assay can shorten the TAT and simplify operation procedure to improve the efficiency of clinical diagnosis when compared with RT-PCR molecular testing, making it more applicable for large-scale testing.

Related Links:
Snibe Diagnostic

New
Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
Pipet Controller
Stripettor Pro

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The breakthrough could result in a higher success rate using a simple oral swab test before IVF (Photo courtesy of Shutterstock)

POC Oral Swab Test to Increase Chances of Pregnancy in IVF

Approximately 15% of couples of reproductive age experience involuntary childlessness. A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.